Monday June 26th 2017

Archive for June, 2015

An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis

An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis

ConclusionAn update on etiology, pathogenesis, diagnosis, and immunomodulatory treatment of MS is presented. Multiple sclerosis is an acquired demyelinating disease of the central nervous system. The etiology of MS is probably multifactorial, related to genetic, [Read More]

A New Targeted Model of Experimental Autoimmune Encephalomyelitis in the Common Marmoset

A New Targeted Model of Experimental Autoimmune Encephalomyelitis in the Common Marmoset

Originally from:  A New Targeted Model of Experimental Autoimmune Encephalomyelitis in the Common Marmoset [Read More]

Optical coherence tomography reflects brain atrophy in MS: A four year study

Optical coherence tomography reflects brain atrophy in MS: A four year study

This article is protected by copyright. All rights reserved. (Source: Annals of Neurology) [Read More]

 Page 1 of 113  1  2  3  4  5 » ...  Last » 

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]